fda restrictions on bpc-157 compounding The Truth About Peptides, Pharmacies, and Regulation The FDA just announced that

Injection site reactions represent the most common adverse effect

Fibroblast Activation: For those looking at tendon or ligament health, this is a significant mechanism

PMID 20092844

Both peptides are banned by WADA and major sports leagues

doi: 10.3389/fpubh.2022.833967 Received 12 December 2021 Accepted 17 January 2022 Published 11 February 2022 Volume 10 - 2022 Edited by Emma Grant, La Trobe University, Australia Reviewed by Xueqin Chen, Ningbo First Hospital, China

Compounded preparations combining BPC-157 and TB-500 are dispensed by licensed 503A pharmacies pursuant to a patient-specific prescription based on a documented clinical evaluation